LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to boost radiation for head and neck cancer
Disease control Recruiting nowThis early-phase trial is testing whether adding the experimental drug ipatasertib to standard chemotherapy and radiation can better control advanced head and neck cancer. About 46 adults with certain types of head and neck cancer will receive the combination to find the safest d…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 10:44 UTC
-
New combo therapy aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis study tests a new approach for people with advanced head and neck cancer that can be surgically removed. Before surgery, patients receive low-dose radiation combined with an immunotherapy drug to shrink the tumor and improve long-term outcomes. The goal is to see if this com…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Xiwei XU • Aim: Disease control
Last updated May 17, 2026 10:39 UTC
-
Could less surgery be better? new trial for head and neck cancer patients
Disease control Recruiting nowThis study compares a less extensive surgery to standard surgery for people with advanced head and neck cancer who have already responded well to immunotherapy and chemotherapy. The goal is to see if the smaller surgery can control the cancer just as well while improving quality …
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Qunxing Li,MD • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Could a double-drug punch shrink head and neck tumors before radiation?
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug (pucotenlimab) to a targeted therapy (MRG003) before standard chemoradiation can shrink tumors more effectively than MRG003 alone in people with advanced head and neck cancer. About 106 adults aged 18–75 will take part. The go…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Tailor-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug aims to stop head and neck cancer relapse after chemoradiation
Disease control Recruiting nowThis study tests a new drug called volrustomig in people with advanced head and neck cancer that has not spread. Participants have finished standard chemoradiation and their cancer has not grown. Half will get volrustomig, half will just be watched. The goal is to see if the drug…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New combo therapy shows promise in fighting advanced head and neck cancer
Disease control Recruiting nowThis study tests whether adding a targeted drug (becotatug vedotin) to standard immunotherapy works better than immunotherapy alone for people with a specific type of advanced head and neck cancer. About 430 adults whose tumors have certain markers (EGFR-positive and CPS≥1) and c…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for elderly cancer patients: experimental therapy targets tumors from the inside
Disease control Recruiting nowThis study tests a new drug, NBTXR3, that is injected directly into tumors and activated by radiation. It is for patients aged 60 and older with advanced head and neck cancer who cannot receive standard chemotherapy. The goal is to see if adding NBTXR3 to radiation therapy helps …
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated May 12, 2026 13:42 UTC